Otavio Berwanger1, Renato D Lopes2, Diogo D F Moia3, Francisco A Fonseca4, Lixin Jiang5, Shaun G Goodman6, Stephen J Nicholls7, Alexander Parkhomenko8, Oleg Averkov9, Carlos Tajer10, Germán Malaga11, Jose F K Saraiva12, Helio P Guimaraes3, Pedro G M de Barros E Silva3, Lucas P Damiani3, Renato H N Santos3, Denise M Paisani3, Tamiris A Miranda3, Nanci Valeis3, Leopoldo S Piegas13, Christopher B Granger14, Harvey D White15, Jose C Nicolau16. 1. Research Institute, Heart Hospital (HCor), São Paulo, Brazil. Electronic address: otavioberwanger@gmail.com. 2. Duke Clinical Research Institute, Durham, North Carolina; Universidade Federal de São Paulo, São Paulo, Brazil. 3. Research Institute, Heart Hospital (HCor), São Paulo, Brazil. 4. Universidade Federal de São Paulo, São Paulo, Brazil. 5. Fuwai Hospital, Beijing, China. 6. Canadian Heart Research Centre (CHRC) and Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. 7. Monash Cardiovascular Research Centre, Monash University, Melbourne, Victoria, Australia. 8. Institute of Cardiology, Emergency Cardiology Department, Kiev, Ukraine. 9. Pirogov Russian National Research Medical University, Moscow, Russia. 10. Hospital de Alta Complejidad El Cruce, Buenos Aires, Argentina. 11. School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru. 12. Hospital e Maternidade Celso Pierro, Campinas, Brazil. 13. Heart Hospital (HCor), São Paulo, Brazil. 14. Duke Clinical Research Institute, Durham, North Carolina. 15. Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand. 16. Instituto do Coração (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Abstract
BACKGROUND: The efficacy of ticagrelor in the long-term post-ST-segment elevation myocardial infarction (STEMI) treated with fibrinolytic therapy remains uncertain. OBJECTIVES: The purpose of this study was to evaluate the efficacy of ticagrelor when compared with clopidogrel in STEMI patients treated with fibrinolytic therapy. METHODS: This international, multicenter, randomized, open-label with blinded endpoint adjudication trial enrolled 3,799 patients (age <75 years) with STEMI receiving fibrinolytic therapy. Patients were randomized to ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) or clopidogrel (300- to 600-mg loading dose, 75 mg daily thereafter). The key outcomes were cardiovascular mortality, myocardial infarction, or stroke, and the same composite outcome with the addition of severe recurrent ischemia, transient ischemic attack, or other arterial thrombotic events at 12 months. RESULTS: The combined outcome of cardiovascular mortality, myocardial infarction, or stroke occurred in 129 of 1,913 patients (6.7%) receiving ticagrelor and in 137 of 1,886 patients (7.3%) receiving clopidogrel (hazard ratio: 0.93; 95% confidence interval: 0.73 to 1.18; p = 0.53). The composite of cardiovascular mortality, myocardial infarction, stroke, severe recurrent ischemia, transient ischemic attack, or other arterial thrombotic events occurred in 153 of 1,913 patients (8.0%) treated with ticagrelor and in 171 of 1,886 patients (9.1%) receiving clopidogrel (hazard ratio: 0.88; 95% confidence interval: 0.71 to 1.09; p = 0.25). The rates of major, fatal, and intracranial bleeding were similar between the ticagrelor and clopidogrel groups. CONCLUSION: Among patients age <75 years with STEMI, administration of ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of cardiovascular events when compared with clopidogrel. (Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated WithPharmacological Thrombolysis [TREAT]; NCT02298088).
RCT Entities:
BACKGROUND: The efficacy of ticagrelor in the long-term post-ST-segment elevation myocardial infarction (STEMI) treated with fibrinolytic therapy remains uncertain. OBJECTIVES: The purpose of this study was to evaluate the efficacy of ticagrelor when compared with clopidogrel in STEMI patients treated with fibrinolytic therapy. METHODS: This international, multicenter, randomized, open-label with blinded endpoint adjudication trial enrolled 3,799 patients (age <75 years) with STEMI receiving fibrinolytic therapy. Patients were randomized to ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) or clopidogrel (300- to 600-mg loading dose, 75 mg daily thereafter). The key outcomes were cardiovascular mortality, myocardial infarction, or stroke, and the same composite outcome with the addition of severe recurrent ischemia, transient ischemic attack, or other arterial thrombotic events at 12 months. RESULTS: The combined outcome of cardiovascular mortality, myocardial infarction, or stroke occurred in 129 of 1,913 patients (6.7%) receiving ticagrelor and in 137 of 1,886 patients (7.3%) receiving clopidogrel (hazard ratio: 0.93; 95% confidence interval: 0.73 to 1.18; p = 0.53). The composite of cardiovascular mortality, myocardial infarction, stroke, severe recurrent ischemia, transient ischemic attack, or other arterial thrombotic events occurred in 153 of 1,913 patients (8.0%) treated with ticagrelor and in 171 of 1,886 patients (9.1%) receiving clopidogrel (hazard ratio: 0.88; 95% confidence interval: 0.71 to 1.09; p = 0.25). The rates of major, fatal, and intracranial bleeding were similar between the ticagrelor and clopidogrel groups. CONCLUSION: Among patients age <75 years with STEMI, administration of ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of cardiovascular events when compared with clopidogrel. (Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis [TREAT]; NCT02298088).
Authors: Kerry K Pickworth; Danielle Blais; Aaron Bagnola; Robert Barcelona; J Michael Boyd; Heidi Brink; Maya Chilbert; Daniel Galipeau; Brooke Gengler; Anthony T Gerlach; Charles Hayes; Joshua Jacobs; Hasan Kazmi; Rachel Lavelle; John Lindsley; Tracy E Macaulay; Michael A Militello; Libby Orzel; Sajni Patel; Pamela Simone; Kristen Tasca; Sara Varnado; Sara Zoubek Journal: J Am Coll Clin Pharm Date: 2020-08-17
Authors: Mohammad Alkhalil; Michał Kuzemczak; Alan Bell; Sol Stern; Michelle Welsford; Warren J Cantor; Shaun G Goodman Journal: CMAJ Date: 2022-02-14 Impact factor: 8.262
Authors: Marco Antonio Scanavini-Filho; Otavio Berwanger; Wilson Matthias; Miguel O Aguiar; Hsu P Chiang; Luciene Azevedo; Luciano M Baracioli; Felipe G Lima; Remo H M Furtado; Talia F Dalcoquio; Fernando R Menezes; Aline G Ferrari; Fabio de Luca; Robert P Giugliano; Shaun Goodman; José C Nicolau Journal: Adv Ther Date: 2022-02-26 Impact factor: 3.845
Authors: Mohammad Alkhalil; Michał Kuzemczak; Alan Bell; Sol Stern; Michelle Welsford; Warren J Cantor; Shaun G Goodman Journal: CMAJ Date: 2022-05-02 Impact factor: 16.859
Authors: Mohammed Ahmed Akkaif; Mei Li Ng; Muhamad Ali Sk Abdul Kader; Nur Aizati Athirah Daud; Abubakar Sha'aban; Baharudin Ibrahim Journal: Pharmacol Rep Date: 2021-07-20 Impact factor: 3.024